Cécile Matthews and Bhavesh Patel were quoted in Pink Sheet regarding their analysis entitled “How do rare disease patient numbers in Germany affect prices for non-oncology orphan drugs?” In Pink Sheet, Matthews and Patel discuss factors to consider when agreeing on a price including benefit ratings, patient populations, and budget impact.
Asembia AXS25: Navigating the Evolving Landscape of GLP-1 Medications
Davis discussed the transition from obesity-specific opt-in benefits to more standard coverage. She expects that payers will need to handle a wider range of...